CoChat

Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study

Open access
Bell, Samira, Farran, Bassam, McGurnaghan, Stuart, McCrimmon, Rory J., Leese, Graham P, Petrie, John R, McKeigue, Paul, Sattar, Naveed, Wild, Sarah, McKnight, John, Lindsay, Robert, Colhoun, Helen M., Looker, Helen · 2017 · BMC Nephrology
Cited by 84

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Whether metformin precipitates lactic acidosis in patients with chronic kidney disease (CKD) remains under debate. We examined whether metformin use was associated with an increased risk of acute kidney injury (AKI) as a proxy for lactic acidosis and whether survival among those with AKI varied by metformin exposure. All individuals with type 2 diabetes and available prescribing data between 2004 and 2013 in Tayside, Scotland were included. The electronic health record for diabetes which includes issued prescriptions was linked to laboratory biochemistry, hospital admission, death register and Scottish Renal Registry data. AKI events were defined using the Kidney Disease Improving Global Outcomes criteria with a rise in serum creatinine of at least 26.5 μmol/l or a rise of greater than 150% from baseline for all hospital admissions. Cox Regression Analyses were used to examine whether person-time periods in which current metformin exposure occurred were associated with an increased rate of first AKI compared to unexposed periods. Cox regression was also used to compare 28 day survival rates following first AKI events in those exposed to metformin versus those not exposed. Twenty-five thousand one-hundred fourty-eight patients were included with a total person-time of 126,904 person years. 4944 (19.7%) people had at least one episode of AKI during the study period. There were 32.4 cases of first AKI/1000pyrs in current metformin exposed person-time periods compared to 44.9 cases/1000pyrs in unexposed periods. After adjustment for age, sex, diabetes duration, calendar time, number of diabetes drugs and baseline renal function, current metformin use was not associated with AKI incidence, HR 0.94 (95% CI 0.87, 1.02, p = 0.15). Among those with incident AKI, being on metformin at admission was associated with a higher rate of survival at 28 days (HR 0.81, 95% CI 0.69, 0.94, p = 0.006) even after adjustment for age, sex, pre-admission eGFR, HbA 1c and diabetes duration. Contrary to common perceptions, we found no evidence that metformin increases incidence of AKI and was associated with higher 28 day survival following incident AKI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12882-017-0579-5

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 84

Metadata

Authors
Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R. J., Leese, G. P., Petrie, J. R., McKeigue, P., Sattar, N., Wild, S., McKnight, J., Lindsay, R., Colhoun, H. M., & Looker, H.
Venue
BMC Nephrology
Published
2017-05-19
Volume
18
Issue
1
Pages
163-163
ISSN
1471-2369 (ISSN-L)
OpenAlex
W2616446856
Cited by
84
References
6
FWCI
6.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. https://app.cochat.ai/papers/10.1186/s12882-017-0579-5
The paper
Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R. J., Leese, G. P., Petrie, J. R., McKeigue, P., Sattar, N., Wild, S., McKnight, J., Lindsay, R., Colhoun, H. M., & Looker, H. (2017). Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology. https://doi.org/10.1186/s12882-017-0579-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.